scholarly journals Lateral differences of breast cancer proliferative activity (KI-67)

2016 ◽  
Vol 97 (4) ◽  
pp. 550-555
Author(s):  
A P Dmitrenko
Keyword(s):  
Breast Cancer ◽  
Proliferative Activity ◽  
Immunohistochemical Study ◽  
Progesterone Receptors ◽  
Ki 67 ◽  
Primary Tumors ◽  
Study Protocols ◽  
Tumor Lesion ◽  
Significant Difference ◽  
The Right

Aim. To determine lateral differences of breast cancer proliferative activity Ki-67.Methods. According to immunohistochemical study protocols analysis of material of 500 patients with breast cancer was conducted. In primary tumors estrogen and progesterone receptors expression, Ki-67, C-erbB-2 was studied.Results.Using two-way analysis of variance, it was found that Ki-67 index was significantly influenced by both side of the tumor lesion (p=0.009) and age of patients (p=0.0002). A higher Ki-67 corresponded to right-sided cancer localization. Statistically significant age differences of Ki-67 index are marked only in right-sided cancer (pConclusion. Statistically significant difference of Ki-67 index in right- and left-sided breast cancer was found, significantly higher Ki-67 was detected in the right-sided tumors, Ki-67 are present only in patients before 60 years.

Ki-67 and mitotic index in triple-positive breast cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12551-e12551
Author(s):  
Maria Mikhailovna Urezkova ◽  
Tatiana Semiglazova ◽  
Anna Artemyeva ◽  
Asel Kudaybergenova
Keyword(s):  
Breast Cancer ◽  
Tumor Cells ◽  
Proliferative Activity ◽  
Group Versus ◽  
Tumor Grade ◽  
Ki 67 ◽  
Development Of Resistance ◽  
Significant Difference ◽  
Histological Malignancy ◽  
Positive Breast Cancer

e12551 Background: A grade in breast cancer is the strongest prognostic factor. In the new edition of the AJCC 8th, the tumor grade is one of the criteria that determines patients with breast cancer in the prognostic groups. According to the Nottingham system the mitotic count (MC) mostly determines the grade. Interobserver reproducibility for MC is not as good as for IHC marker phh3. The group of triple-positive breast cancer (TPBC) is characterized by the presence of a crosstalk mechanism between the signaling pathways of ER and HER2, which leads to the development of resistance to therapy. However, according to the 8th AJCC, patients with ER+/HER2+ belong to a more favorable prognostic group. Methods: We selected 284 patients with early BC who received treatment at our centre from 2012 to 2020 and didn’t receive presurgical therapy. The patients were divided according to the surrogate subtype into triple-positive (n = 90) and other subtypes (n = 194). The Ki-67, the number of nuclei of tumor cells stained with anti-phh3 antibody, the cell density of the tumor per 1 mm2 and the number of phh3 + per 1000 tumor cells were assessed. Results: Visually accessed number of mitoses was grade 3 in 30% of tumors in the TPBC group and 29% in the second group. There was no statistically significant difference in the Ki-67 index of proliferative activity in the two studied groups. In the TPBC group the median Ki-67 was 16.8%, in the second group - 18.3% (p = 0.376516), while the groups differed significantly in terms of the phh3 index (the median in the TPBC was 23.7/mm2, the median in the second group - 16.06/mm2, p = 0.024703). The groups also significantly differed in the number of nuclei of tumor cells that directly entered the mitotic phase (5.1/1000 nuclei in the TPBC group versus 3.2/1000 nuclei in the second group, p = 0.003901). Conclusions: Despite similar indices of proliferative activity in the TPBC and non-TPBC groups, mitotic activity and the number of directly dividing tumor cells in the TPBC group are significantly higher than in the rest of the BC population. Considering the criteria for assessing phh3 (MC 1 < 4/mm2, MC 2 2 4 to 7/mm2, MC 3 > 7/mm2), most TPBCs will have a histological malignancy grade of 3, which according to AJCC 8th places them in the group of poor outcome. We suggest that these differences may be due to the crosstalk mechanism. The second conclusion of our study is the fact that Ki-67 is a poor predictor of the MC.

scholarly journals Müllerian adenosarcoma of the uterus with sarcomatous overgrowth following tamoxifen treatment for breast cancer

2000 ◽  
Vol 55 (1) ◽  
pp. 17-20 ◽  
Author(s):  
Filomena Marino Carvalho ◽  
Jesus Paula Carvalho ◽  
Eduardo Vieira da Motta ◽  
Jorge Souen
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Estrogen Receptors ◽  
Stromal Cells ◽  
Proliferative Activity ◽  
Immunohistochemical Study ◽  
Tamoxifen Treatment ◽  
Ki 67 ◽  
Total Hysterectomy ◽  
Mesenchymal Neoplasms

Müllerian adenosarcoma with sarcomatous overgrowth presented by a 52-year-old female patient after adjuvant tamoxifen treatment for breast carcinoma is described. The diagnosis was made on histological basis after curettage and complementary total hysterectomy with bilateral salpingo-oophorectomy. The immunohistochemical study showed high expression of estrogen receptors in the epithelial component of the lesion and irregularly positive findings in the stroma. The proliferative activity evaluated by Ki-67 immunoexpression was higher in the stroma than the epithelium. Some of the stromal cells showed rhabdomyoblastic differentiation. The association of tamoxifen use and development of mesenchymal neoplasms is discussed.

scholarly journals Age-Related Biology of Early-Stage Operable Breast Cancer and Its Impact on Clinical Outcome

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1417
Author(s):  
Binafsha M. Syed ◽  
Andrew R. Green ◽  
Emad A. Rakha ◽  
David A.L. Morgan ◽  
Ian O. Ellis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Histological Grade ◽  
Survival Rates ◽  
Growth Factor Receptor ◽  
Progesterone Receptors ◽  
Biological Characteristics ◽  
Cancer Specific Survival ◽  
Age Related ◽  
Significant Difference

As age advances, breast cancer (BC) tends to change its biological characteristics. This study aimed to explore the natural progression of such changes. The study included 2383 women with clinically T0-2N0-1M0 BC, managed by primary surgery and optimal adjuvant therapy in a dedicated BC facility. Tissue micro-arrays were constructed from their surgical specimens and indirect immunohistochemistry was used for analysis of a large panel (n = 16) of relevant biomarkers. There were significant changes in the pattern of expression of biomarkers related to luminal (oestrogen receptor (ER), progesterone receptors (PgR), human epidermal growth factor receptor (HER-2), E-cadherin, MUC1, bcl2 CK7/8, CK18 and bcl2) and basal (CK5/6, CK14, p53 and Ki67) phenotypes, lymph node stage, histological grade and pathological size when decade-wise comparison was made (p < 0.05). The ages of 40 years and 70 years appeared to be the milestones marking a change of the pattern. There were significantly higher metastasis free and breast cancer specific survival rates among older women with ER positive tumours while there was no significant difference in the ER negative group according to age. Biological characteristics of BC show a pattern of change with advancing age, where 40 years and 70 years appear as important milestones. The pattern suggests <40 years as the phase with aggressive phenotypes, >70 years as the less aggressive phase and 40–70 years being the transitional phase.

Prognostic subset of metastatic and non-metastatic luminal B breast cancer (LBBC) subtype based on Ki67 index.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12570-e12570
Author(s):  
Lalnun Puii ◽  
Lalram Sangi ◽  
Hrishi Varayathu ◽  
Samuel Luke Koramati ◽  
Beulah Elsa Thomas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Disease ◽  
Ki67 Index ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Her2 Positive ◽  
Ki 67 ◽  
Luminal B ◽  
Therapeutic Implications ◽  
Significant Difference

e12570 Background: Gene expression profiling for breast cancer has classified ER positive subtype into luminal A and luminal B. Luminal B breast cancer (LBBC) have a higher proliferation and poorer prognosis than luminal A tumors. Ki-67 index is the commonly used proliferation marker in breast cancer; however Ki67 expression can also be used to identify a subset of patients among LB with a favorable prognosis. This study attempts to verify this subset of LBBC patients based on DFS and PFS in non-metastatic and metastatic patients respectively. Methods: We retrospectively analyzed 80 IDC breast cancer patients diagnosed in 2013-2016 with complete follow-up till January-2021. We defined LBBC as ER+, PR+ or PR- , HER2+ or HER2- with a Ki67 index >20%. PFS was considered as the endpoint in patients presenting with metastatic disease whereas DFS was used in non-metastatic disease. The cut-off for ki67 was calculated using an X-tile plot (version 3.6.1, Yale University) by dividing Ki67 data into two populations: low and high, with randomized 1:1 “training” and “validation” cohorts. Results: Median age was 51.5 years. 18.7% (n=15) presented with metastasis at the time of diagnosis and their overall median PFS was found to be 25.8 months. The incidence of HER2 positive LBBC was found to be 15% (n=12) and none of them were found to be presented with metastasis. Survival and frequency of various sub groups in our study are enlisted in the given table. We estimated a Ki67 cut-off of 30% in patients with upfront metastatic disease and PFS was found to be higher in <30% compared to a Ki67 index >30% (38.9 months vs 19.7 months, p-0.002). Overall median DFS was not achieved in non-metastatic group (Mean DFS: 64.7 months) where as a statistically significant difference was observed in the survival of HER2 positive (median DFS: 53.5 months, mean DFS: 50.9) than HER2 negative patients (median DFS not achieved, mean: 66.97 months) ( p-0.021). We obtained a Ki67 cut-off of 32% in non- metastatic group and mean DFS was found to be higher in Ki67<32% (69 months) compared to Ki67>32% (61.4 months), however it failed to exhibit a statistically significant relationship ( p-0.373). Conclusions: Our study indicates that a subset of patients exists within metastatic and non-metastatic LBBC with differing prognosis based on Ki67. Larger studies are further required to confirm the findings and therapeutic implications.[Table: see text]

scholarly journals Quantitative and dosimetric analysis for treating synchronous bilateral breast cancer using two radiotherapy planning techniques

2021 ◽  
Vol 27 (3) ◽  
pp. 201-206
Author(s):  
Özlem Mermut ◽  
Aysun Ozsoy Ata ◽  
Didem Can Trabulus
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Organs At Risk ◽  
Bilateral Breast Cancer ◽  
Radiotherapy Planning ◽  
Conformity Index ◽  
Treatment Unit ◽  
Significant Difference ◽  
Synchronous Bilateral Breast Cancer ◽  
The Right

Abstract Objective: We compared mono-isocenter and dual-isocenter plans in synchronous bilateral breast cancer (SBBC), which is defined as tumours occurring simultaneously in both breasts, and evaluated the effects of these differences in plans on organs-at-risk (OARs). Materials and methods: We evaluated 10 women with early stage, nod negative (Tis-2N0M0) SBBC. The treatment dose was determined to be 50 Gy. We used mean dose and VXGy to evaluate the OARs. To evaluate the effectiveness of treatment plans, Homogeneity index (HI), conformity index (CI) and sigma index (SI) and monitor units (MU) of monoisocenter (MIT) and dual-isocenter (DIT) plans were compared. During bilateral breast planning, for the single-centre plan, the isocenter was placed at the center of both breasts at a depth of 3-4 cm. For the two-center plan, dual-isocenters were placed on the right and left breasts. Results: No significant difference between the techniques in terms of the scope of the target volume was observed. Statistically significant results were not achieved in MIT and DIT plans for OARs. Upon comparing MIT and DIT, the right-side monitor unit (MU) value in DIT (p = 0.011) was statistically significantly lower than that in MIT. Upon comparing right-left side MIT and DIT, the MU value (p = 0.028) was significantly lower in DIT than MIT. Conclusion: SBBC irradiation is more complex than unilateral breast radiotherapy. No significant difference between both techniques and OARs was observed. However, we recommend MIT as a priority technique due to the ability to protect OARs, ease of administration during treatment, and the fact that the patient stays in the treatment unit for a shorter period of time.

scholarly journals Immunoistochemical and morphological study of periodont tissues when predicting the results of dental implantation in patients with chronic parodontitis

2019 ◽  
Vol 488 (4) ◽  
pp. 452-456
Author(s):  
A. A. Kulakov ◽  
E. A. Kogan ◽  
T. V. Brailovskaya ◽  
A. P. Vedyaeva ◽  
N. V. Zharkov
Keyword(s):  
Proliferative Activity ◽  
Morphological Study ◽  
Immunohistochemical Study ◽  
Additional Treatment ◽  
Paraffin Sections ◽  
Regenerative Capacity ◽  
Ki 67 ◽  
Dental Implantation ◽  
Growth Zones ◽  
Severe Degree

A morphological and immunohistochemical study of 24 gums biopsies was conducted in 19 patients aged 35-60 years with a diagnosis of partial secondary edentulous, chronic generalized periodontitis of moderate and severe degree (14 patients), and also without pathological changes in the periodontal disease (5 patients), who underwent dental implantation. Immunohistochemical reactions with antibodies to Ki-67, VEGF, SMA were performed on serial paraffin sections. It has been established that chronic periodontitis is characterized by a higher proliferative activity of the epithelium, which reflects its hyperplastic changes, as well as a lower content of SMA positive cells and the practical absence of the formation of privascular couplings from SMA-positive cells that are associated in tissues with growth zones, which indirectly indicates reduced tissue regenerative capacity. Therefore, in the case of the operation of dental implantation requires additional treatment aimed at anti-inflammatory and pro-regenerative effects.

Distribution of Estrogen and Progesterone Receptors in Primary Tumor and Lymph Nodes in Individual Patients with Breast Cancer

1984 ◽  
Vol 70 (2) ◽  
pp. 165-168 ◽  
Author(s):  
Danila Coradini ◽  
Vera Cappelletti ◽  
Patrizia Miodini ◽  
Enrico Ronchi ◽  
Gianfranco Scavone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Primary Tumor ◽  
Progesterone Receptors ◽  
Cancer Tissue ◽  
Primary Tumors ◽  
Er Positive ◽  
Malignant Lymph Nodes ◽  
Negative Lymph Nodes ◽  
Primary Breast Cancer Tissue

Primary breast cancer tissue and lymph nodes were obtained from 48 patients. Estrogen receptors (ER) and progesterone receptors (PgR) were determined by a dextran-coated charcoal assay. ER were present in 72.9 % of the primary tumors and in 62.4 % of the malignant lymph nodes, whereas PgR were present in 73.0 % and 50.0 % of the cases, respectively. The primary tumor and the corresponding malignant lymph nodes showed an identical ER and PgR status, i.e., both tumor sites were receptor positive or both receptor negative in 89.6 % and 77.1 %, respectively. However, 10.4 % of the patients had ER-positive tumors but ER-negative lymph nodes and 22.9 % had PgR-positive primaries with PgR-negative lymph nodes. No receptor-positive lymph nodes showed a combination with receptor-negative primary tumor. This preliminary data shows that receptor-positive malignant lymph nodes mostly display the same receptor status as the corresponding primary tumor, whereas receptor-negative lymph nodes may have a receptor-positive primary tumor.

Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor marker

2002 ◽  
Vol 12 (1) ◽  
pp. 74-79
Author(s):  
C Dimas ◽  
M Frangos-Plemenos ◽  
E Kouskouni ◽  
A Kondis-Pafitis
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Primary Breast Cancer ◽  
Immunohistochemical Study ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Progesterone Receptors ◽  
Her2 Overexpression ◽  
Serum Tumor Marker ◽  
Degree Of Differentiation

Abstract.Dimas C, Frangos-Plemenos M, Kouskouni E, Kondis-Pafitis A. Immunohistochemical study of p185 HER2 and DF3 in primary breast cancer and correlation with CA-15-3 serum tumor marker.Human epidermal growth factor receptor 2 (p185 HER2) oncoprotein immunohistochemical expression and DF3 antigen distribution were evaluated in 129 patients with primary breast cancer. p185 HER2 overexpession was positively correlated with the degree of differentiation, metastatic disease, progesterone receptors, and cytoplasmic distribution of DF3 antigen. p185 HER2 overexpression had prognostic significance for the disease-free interval.

Patterns of HER2/neu, hormonal receptor expression, and proliferative activity in primary and metastatic breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1071-1071
Author(s):  
F. Giotta ◽  
G. Simone ◽  
V. Fazio ◽  
S. Longo ◽  
S. Petroni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Predictive Factors ◽  
Proliferative Activity ◽  
Metastatic Breast ◽  
Receptor Expression ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Prognostic And Predictive Factors ◽  
Mib 1

1071 Background: The modification of biological features of metastatic sites (MS) in breast cancer patients arise some debatable questions regarding clinically usefull information and safe/efficient methods to detect them. Fine needle aspiration (FNA) of visceral MS is an available tool to characterize tumoral lesion and liquid based citology technique provides usefull cell samples for immunocytochemical and/or molecular assays. Methods: The aim of this study was to compare prognostic and predictive factors obtained from primary tumors (PT) and corresponding MS. Fluorescent in situ hybridization (FISH) was performed for HER2/Neu determination, while ER, PgR, and MIB-1 were detected by immunochemistry using specific monoclonal antibodies on monolayered cell sample and in the corresponding cytoinclusion. FNA with a 21–23 G needle was performed in 20 consecutive breast cancer patients with distant metacronous MS. Results: In 8/20 patients, both ER and PgR were absent in PT and in MS, in 7 were both present, in 4 cases only ER was detected, and only 1 case was ER negative with a low PgR. About the proliferative activity (MIB-1 index: cut off value >20%) only 3 MS presented an higher value. With regard to HER2/Neu, 4/20 cases were amplified and no discrepancies were found between cytological and cytoinclusion specimens. No substantial changes were found about kinetic activity. HER2/Neu status as assessed in PT was confirmed in MS in 10/12 cases; a lung mestastasis showed amplification while primary was not amplified and a liver lesion lost the amplification which was detected in the PT. Conclusions: Our study strongly suggest the opportunity in using FNA for detection of prognostic and predictive factors in MS. Pectasides et al. (Anticancer Res. 2006) found in patients with altered or conserved HER2/Neu in PT and in MS different response rates between the two groups and a significant poorer prognosis in patients with altered Neu. We think that liquid-based cytology applied on FNA of distant metastases could help us to understand some more in this issue. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document